Class information for:
Level 1: CD20//OFATUMUMAB//OBINUTUZUMAB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
6639 1389 44.4 88%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1265 8379 CHRONIC LYMPHOCYTIC LEUKEMIA//HAIRY CELL LEUKEMIA//CLL

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CD20 Author keyword 51 29% 11% 152
2 OFATUMUMAB Author keyword 18 45% 2% 30
3 OBINUTUZUMAB Author keyword 12 58% 1% 14
4 CD20 EXPRESSION Author keyword 8 75% 0% 6
5 ADCC Author keyword 7 13% 4% 52
6 LATE ONSET NEUTROPENIA Author keyword 7 64% 1% 7
7 RITUXAN Author keyword 7 46% 1% 11
8 CD20 ANTIGEN Author keyword 7 39% 1% 13
9 GA101 Author keyword 6 80% 0% 4
10 ANTI CD20 Author keyword 3 15% 2% 21

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CD20 51 29% 11% 152 Search CD20 Search CD20
2 OFATUMUMAB 18 45% 2% 30 Search OFATUMUMAB Search OFATUMUMAB
3 OBINUTUZUMAB 12 58% 1% 14 Search OBINUTUZUMAB Search OBINUTUZUMAB
4 CD20 EXPRESSION 8 75% 0% 6 Search CD20+EXPRESSION Search CD20+EXPRESSION
5 ADCC 7 13% 4% 52 Search ADCC Search ADCC
6 LATE ONSET NEUTROPENIA 7 64% 1% 7 Search LATE+ONSET+NEUTROPENIA Search LATE+ONSET+NEUTROPENIA
7 RITUXAN 7 46% 1% 11 Search RITUXAN Search RITUXAN
8 CD20 ANTIGEN 7 39% 1% 13 Search CD20+ANTIGEN Search CD20+ANTIGEN
9 GA101 6 80% 0% 4 Search GA101 Search GA101
10 ANTI CD20 3 15% 2% 21 Search ANTI+CD20 Search ANTI+CD20

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ANTI CD20 MONOCLONAL ANTIBODY 101 24% 27% 373
2 CD20 78 43% 10% 140
3 IDEC C2B8 63 48% 7% 98
4 FC GAMMA RIIIA 47 36% 8% 106
5 RITUXIMAB IN VIVO 38 86% 1% 19
6 HUMAN CD20 34 60% 3% 37
7 THERAPEUTIC ACTIVITY 23 30% 5% 65
8 C RECEPTOR POLYMORPHISMS 21 43% 3% 38
9 COATED TARGET CELLS 20 100% 1% 9
10 ANTI CD20 ANTIBODY 14 24% 4% 50

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer 2013 41 48 54%
From the bench to the bedside: ways to improve rituximab efficacy 2004 303 94 67%
Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody 2015 1 30 83%
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance 2003 310 65 69%
New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies 2011 29 62 89%
'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions' 2007 110 37 68%
Anti-CD20 monoclonal antibodies: historical and future perspectives 2010 69 98 66%
Rituximab: Mechanism of action and resistance 2002 211 27 78%
Mechanisms of action of CD20 antibodies 2012 30 114 65%
Neutropenia after rituximab treatment: new insights on a late complication 2012 26 44 68%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 EA3853 3 100% 0.2% 3
2 SERV HEMATOL BIOTHER IES 3 100% 0.2% 3
3 MOL IMMUNOHAEMATOL 3 50% 0.3% 4
4 ANTIBODY VACCINE GRPCANC SCI UNIT 3 60% 0.2% 3
5 TENOVUS CANC SCI 3 42% 0.4% 5
6 LYMPHOMA MYELOMA SERV 3 35% 0.4% 6
7 MOL GENET IMMUNOL 3 13% 1.3% 18
8 SECT STEM CELL TRANSPLANTAT IMMUNOTHER Y 2 38% 0.4% 5
9 CRUK PATERSON CANC 2 67% 0.1% 2
10 GENENTECH BIOONCOL 2 67% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000184221 FLUDARABINE//CHRONIC LYMPHOCYTIC LEUKEMIA//CLADRIBINE
2 0.0000159003 FOLLICULAR LYMPHOMA//NON HODGKINS LYMPHOMA//AGGRESSIVE NON HODGKINS LYMPHOMA
3 0.0000132640 RADIOIMMUNOTHERAPY//PRETARGETING//Y 90 IBRITUMOMAB TIUXETAN
4 0.0000122894 U396//HU1D10//UNITE 396
5 0.0000101286 AGALACTOSYL IGG//PROT ANALYT CHEM//IGG GLYCOSYLATION
6 0.0000095958 BAFF//APRIL//BLYS
7 0.0000094138 BENDAMUSTINE//TREANDA//BENDAMUSTIN
8 0.0000081448 BISPECIFIC ANTIBODIES//CATUMAXOMAB//TRIFUNCTIONAL ANTIBODY
9 0.0000077932 ANTIBODY DRUG CONJUGATE//ANTIBODY DRUG CONJUGATES//T DM1
10 0.0000070460 IDIOTYPE//IDIOTYPE VACCINATION//CELL THER Y AREA